Key Points
- The federal government has approved the monovalent vaccines, which target Omicron variants.
- The new XBB 1.5 vaccines have been found to provide modest improved protection against the strains currently circulating.
- Only about a quarter of vulnerable Australians have had their 2023 booster shots.
The latest COVID-19 vaccines targeting common variants of the virus will be made available to Australians from next month.
Federal Health Minister Mark Butler says the government has approved the monovalent vaccines, which target Omicron subvariants, after taking advice from the Australian Technical Advisory Group on Immunisation (ATAGI).
The shots would help protect Australians against the current strains of the virus and demonstrated the government's ongoing commitment to providing the latest and most effective vaccines, Butler said.
"While we are no longer in the emergency phase of this pandemic, COVID-19 is still present, and people should continue to follow the advice of the experts from ATAGI, including getting vaccines as required."
However, authorities say only about a quarter of vulnerable Australians have had their 2023 booster shots amid a surge in cases.
With more than 800,000 COVID notifications so far this year, hospitalisations have dropped from more than 400 in January but are again on the rise, with about 160 people in care at the start of November.
The new XBB 1.5 vaccines will be available from 11 December, and Butler said they have been found to provide modest improved protection against the strains currently circulating in the community.
People who have already had their 2023 vaccination(s) don't need to get jabbed again and remain well protected against severe disease.
Pfizer's monovalent XBB.1.5 vaccine will be available for use in eligible Australians five years and older, while the Moderna monovalent XBB.1.5 vaccine can be used for those aged 12 and older.
